Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents
- PMID: 31506871
- PMCID: PMC11177332
- DOI: 10.1007/s11030-019-09990-z
Design, synthesis, in silico and in vitro evaluation of novel diphenyl ether derivatives as potential antitubercular agents
Abstract
Diphenyl ether derivatives inhibit mycobacterial cell wall synthesis by inhibiting an enzyme, enoyl-acyl carrier protein reductase (InhA), which catalyses the last step in the fatty acid synthesis cycle of genus Mycobacterium. To select and validate a protein crystal structure of enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis for designing inhibitors using molecular modelling, a cross-docking and correlation study was performed. A series of novel 1-(3-(3-hydroxy-4-phenoxyphenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-1-yl) ethan-1-ones were synthesized from this model and screened for their antitubercular activity against M. tuberculosis H37Rv. Compound PYN-8 showed good antitubercular activity on M. tuberculosis H37Rv (MIC = 4-7 µM) and Mycobacterium bovis (% inhibition at 10 µM = 95.91%). Cytotoxicity of all the synthesized derivatives was assessed using various cell lines, and they were found to be safe. Structure of PYN-8 was also confirmed by single-crystal X-ray diffraction. The molecular modelling studies also corroborated the biological activity of the compounds. Further, in silico findings revealed that all these tested compounds exhibited good ADME properties and drug likeness and thus may be considered as potential candidates for further drug development.
Keywords: Antitubercular; Correlation study; Diphenylether; InhA; Molecular docking; TB.
Conflict of interest statement
Conflict of Interest
The authors confirm that this article content has no conflict of interest.
Figures









References
-
- WHO | Tuberculosis (TB). WHO [Internet]. World Health Organization; 2018. [cited 2019 Mar 1]; Available from: https://www.who.int/gho/tb/en/
-
- World Health Organization. BCG vaccine: WHO position paper, February 2018 – Recommendations. Vaccine. 2018. - PubMed
-
- WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care. World Health Organization. 2017.
-
- Rožman K, Sosič I, Fernandez R, Young RJ, Mendoza A, Gobec S, et al. A new ‘golden age’ for the antitubercular target InhA. Drug Discovery Today. 2017. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical